Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
FRESENIUS KABI ONCO. | GSK PHARMA | FRESENIUS KABI ONCO./ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 22.1 | 53.5 | 41.4% | View Chart |
P/BV | x | 3.1 | 12.1 | 25.8% | View Chart |
Dividend Yield | % | 0.0 | 1.3 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
FRESENIUS KABI ONCO. Mar-13 |
GSK PHARMA Mar-19 |
FRESENIUS KABI ONCO./ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 176 | 3,595 | 4.9% | |
Low | Rs | 79 | 1,253 | 6.3% | |
Sales per share (Unadj.) | Rs | 37.7 | 184.7 | 20.4% | |
Earnings per share (Unadj.) | Rs | 5.1 | 26.3 | 19.4% | |
Cash flow per share (Unadj.) | Rs | 6.7 | 29.2 | 23.1% | |
Dividends per share (Unadj.) | Rs | 0 | 20.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 42.5 | 126.3 | 33.7% | |
Shares outstanding (eoy) | m | 158.23 | 169.40 | 93.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.4 | 13.1 | 25.7% | |
Avg P/E ratio | x | 25.0 | 92.2 | 27.1% | |
P/CF ratio (eoy) | x | 18.9 | 83.1 | 22.8% | |
Price / Book Value ratio | x | 3.0 | 19.2 | 15.6% | |
Dividend payout | % | 0 | 76.1 | 0.0% | |
Avg Mkt Cap | Rs m | 20,135 | 410,626 | 4.9% | |
No. of employees | `000 | 1.2 | 5.0 | 23.2% | |
Total wages/salary | Rs m | 703 | 5,372 | 13.1% | |
Avg. sales/employee | Rs Th | 5,176.2 | 6,306.7 | 82.1% | |
Avg. wages/employee | Rs Th | 610.4 | 1,083.1 | 56.4% | |
Avg. net profit/employee | Rs Th | 699.6 | 898.0 | 77.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,963 | 31,281 | 19.1% | |
Other income | Rs m | 18 | 1,023 | 1.8% | |
Total revenues | Rs m | 5,981 | 32,304 | 18.5% | |
Gross profit | Rs m | 1,430 | 6,009 | 23.8% | |
Depreciation | Rs m | 258 | 486 | 53.1% | |
Interest | Rs m | -26 | 6 | -433.3% | |
Profit before tax | Rs m | 1,216 | 6,540 | 18.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -68 | 287 | -23.7% | |
Tax | Rs m | 342 | 2,373 | 14.4% | |
Profit after tax | Rs m | 806 | 4,454 | 18.1% | |
Gross profit margin | % | 24.0 | 19.2 | 124.9% | |
Effective tax rate | % | 28.1 | 36.3 | 77.5% | |
Net profit margin | % | 13.5 | 14.2 | 94.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 5,102 | 20,061 | 25.4% | |
Current liabilities | Rs m | 2,385 | 14,543 | 16.4% | |
Net working cap to sales | % | 45.6 | 17.6 | 258.2% | |
Current ratio | x | 2.1 | 1.4 | 155.0% | |
Inventory Days | Days | 150 | 57 | 264.3% | |
Debtors Days | Days | 113 | 14 | 805.7% | |
Net fixed assets | Rs m | 5,148 | 14,343 | 35.9% | |
Share capital | Rs m | 158 | 1,694 | 9.3% | |
"Free" reserves | Rs m | 6,556 | 19,704 | 33.3% | |
Net worth | Rs m | 6,732 | 21,398 | 31.5% | |
Long term debt | Rs m | 952 | 2 | 47,610.0% | |
Total assets | Rs m | 10,388 | 39,113 | 26.6% | |
Interest coverage | x | -45.8 | 1,091.0 | -4.2% | |
Debt to equity ratio | x | 0.1 | 0 | 151,337.3% | |
Sales to assets ratio | x | 0.6 | 0.8 | 71.8% | |
Return on assets | % | 7.5 | 11.4 | 65.8% | |
Return on equity | % | 12.0 | 20.8 | 57.5% | |
Return on capital | % | 14.6 | 31.9 | 45.7% | |
Exports to sales | % | 74.5 | 0 | - | |
Imports to sales | % | 24.8 | 0 | - | |
Exports (fob) | Rs m | 4,441 | NA | - | |
Imports (cif) | Rs m | 1,477 | NA | - | |
Fx inflow | Rs m | 5,298 | 534 | 992.1% | |
Fx outflow | Rs m | 1,772 | 7,091 | 25.0% | |
Net fx | Rs m | 3,525 | -6,557 | -53.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,274 | 3,994 | 31.9% | |
From Investments | Rs m | -1,204 | -1,433 | 84.0% | |
From Financial Activity | Rs m | -196 | -3,584 | 5.5% | |
Net Cashflow | Rs m | -126 | -1,023 | 12.3% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 81.0 | 50.7 | 159.8% | |
Indian inst/Mut Fund | % | 0.3 | 10.2 | 2.9% | |
FIIs | % | 9.6 | 23.8 | 40.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 15.4 | 59.1% | |
Shareholders | 42,599 | 102,036 | 41.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare FRESENIUS KABI ONCO. With: CADILA HEALTHCARE TTK HEALTHCARE SHASUN PHARMA BIOCON FULFORD INDIA
Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets continued their momentum and ended their day on a strong note today.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More